1. Christian Blank -Combi IPI/NIVO as neoadjuvant -OpACIN trial
Combi ipilimumab and nivolumab produces more side effects in neoadjuvant setting.
Small study, 20 patients
-for stage III, rezectable, with palpable limphnodes
Main goals of neoadjuvant therapies
- to reduce the microscopic disease.
- to better control the local disease
Too small to get relevant results, still promising - Recurrence Free Survival (RFS), 1 year 56%.
2. A. Ribas. Genomic features of complete responders versus fast progressors in patients with Braf mutated melanoma treated with Vemurafenib/cobimetinib versus vemurafenib alone.
Mutational load predictor was the same in patient with complete response and the ones who were progressing- analyzing biopsies.
Interesting - Disease Progression (PD)
was related to keratinization or keratine signature
Complete responses (CR) were seen in patients with multiple gene signatures
To be continued..